西安瑞联新材料股份有限公司 独立董事 2024 年度述职报告 （梅雪锋） 作为西安瑞联新材料股份有限公司（以下简称"公司"）第三届董事会独立 董事，我在任职期间严格按照《公司法》《证券法》《上海证券交易所科创板股 票上市规则》《上市公司独立董事管理办法》等法律法规和《公司章程》《独立 董事工作制度》的要求，我始终恪守独立、客观、公正的原则，积极出席相关会 议，参与公司治理，充分发挥专业优势，认真审议董事会、专门委员会及独董专 门会各项议案，对公司重大事项发表独立意见，审慎决策，切实维护公司及全体 股东，尤其是中小股东的合法权益。现将本人 2024 年度履行独立董事职责的情 况报告如下： 一、独立董事的基本情况 （一）独立董事人员情况 公司第三届董事会共由 9 名董事组成，其中独立董事 3 人，独立董事占董事 会成员的比例不低于三分之一且包括一名会计专业人士，符合相关法律法规及公 司制度的规定。公司第三届董事会任期已于 2024 年 8 月 2 日届满，鉴于公司尚 未完成新一届董事会的换届选举工作，为保证董事会相关工作的连续性和稳定 性，目前第三届董事会独立董事仍继续履职。 （二）个人工作履历、专业背景及兼职情 ...

作为西安瑞联新材料股份有限公司（以下简称"公司"）第三届董事会独立 董事，我在任职期间严格按照《公司法》《证券法》《上海证券交易所科创板股 票上市规则》《上市公司独立董事管理办法》等法律法规和《公司章程》《独立 董事工作制度》的要求，我始终恪守独立、客观、公正的原则，积极出席相关会 议，参与公司治理，充分发挥专业优势，认真审议董事会、专门委员会及独董专 门会各项议案，对公司重大事项发表独立意见，审慎决策，切实维护公司及全体 股东，尤其是中小股东的合法权益。现将本人 2024 年度履行独立董事职责的情 况报告如下： 一、独立董事的基本情况 （一）独立董事人员情况 公司第三届董事会共由 9 名董事组成，其中独立董事 3 人，独立董事占董事 会成员的比例不低于三分之一且包括一名会计专业人士，符合相关法律法规及公 司制度的规定。公司第三届董事会任期已于 2024 年 8 月 2 日届满，鉴于公司尚 未完成新一届董事会的换届选举工作，为保证董事会相关工作的连续性和稳定性， 目前第三届董事会独立董事仍继续履职。 （二）个人工作履历、专业背景及兼职情况 西安瑞联新材料股份有限公司 独立董事 2024 年度述职报告 （肖宝强 ...

一、独立董事的基本情况 （一）独立董事人员情况 公司第三届董事会共由 9 名董事组成，其中独立董事 3 人，独立董事占董事 会成员的比例不低于三分之一且包括一名会计专业人士，符合相关法律法规及公 司制度的规定。公司第三届董事会任期已于 2024 年 8 月 2 日届满，鉴于公司尚 未完成新一届董事会的换届选举工作，为保证董事会相关工作的连续性和稳定性， 目前第三届董事会独立董事仍继续履职。 西安瑞联新材料股份有限公司 独立董事 2024 年度述职报告 （李政） 作为西安瑞联新材料股份有限公司（以下简称"公司"）第三届董事会独立 董事，本人在任职期间严格按照《公司法》《证券法》《上海证券交易所科创板股 票上市规则》《上市公司独立董事管理办法》等法律法规和《公司章程》《独立董 事工作制度》的要求，我始终恪守独立、客观、公正的原则，积极出席相关会议， 参与公司治理，充分发挥专业优势，认真审议董事会、专门委员会及独董专门会 各项议案，审慎决策，切实维护公司及全体股东，尤其是中小股东的合法权益。 现将本人 2024 年度履行独立董事职责的情况报告如下： （二）个人工作履历、专业背景及兼职情况 李政，女，1964 年 6 ...

西安瑞联新材料股份有限公司 章程 西安瑞联新材料股份有限公司章程 第一章 总则 | 第一条 | 为维护公司、股东、职工和债权人的合法权益，规范公司的组织和行 | | --- | --- | | | 为，根据《中华人民共和国公司法》(下称《公司法》)、《中华人民 | | | 共和国证券法》(下称《证券法》)和其他有关规定，制订本章程。 | | 第二条 | 西安瑞联新材料股份有限公司(下称"公司""上市公司")系依照《公 | | | 司法》《证券法》和其他有关规定成立的股份有限公司。 | | | 公司系由原西安瑞联近代电子材料有限责任公司整体变更成立的股 | | | 份有限公司，在西安市市场监督管理局注册登记，取得企业法人营业 | | | 执照，统一社会信用代码 91610131628053714D。 | | 第三条 | 公司于 2020 年 7 月 28 日经中国证券监督管理委员会同意注册，首次 | | | 向社会公众发行人民币普通股 万股。于 年 月 日在上 1,755 2020 9 2 | | | 海证券交易所(下称"证券交易所")上市。 | | 第四条 | 公司注册名称： | | | 中文全称：西安瑞联新 ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 343,971,618.35, representing a 4.83% increase compared to CNY 328,126,092.09 in the same period last year[4] - Net profit attributable to shareholders was CNY 45,631,603.32, a 32.90% increase from CNY 34,334,209.63 year-on-year[4] - The net profit after deducting non-recurring gains and losses was CNY 42,005,544.52, reflecting a 32.48% increase compared to CNY 31,706,067.84 in the previous year[4] - Total operating revenue for Q1 2025 reached ¥343,971,618.35, an increase of 4.3% compared to ¥328,126,092.09 in Q1 2024[20] - Net profit for Q1 2025 was ¥45,631,603.32, representing a 32.9% increase from ¥34,334,209.63 in Q1 2024[21] - Earnings per share for Q1 2025 were ¥0.26, compared to ¥0.25 in Q1 2024, indicating a slight improvement[22] Cash Flow - The net cash flow from operating activities decreased by 21.94% to CNY 31,250,049.75 from CNY 40,035,197.98 in the same period last year[4] - The company reported a net cash inflow from operating activities, indicating positive cash flow management during the quarter[23] - Operating cash inflow totaled ¥249,531,721.81, an increase from ¥229,302,977.57 year-over-year[24] - Operating cash outflow amounted to ¥218,281,672.06, compared to ¥189,267,779.59 in the previous period[24] - Net cash flow from operating activities was ¥31,250,049.75, down from ¥40,035,197.98 year-over-year[24] - Cash inflow from investment activities reached ¥507,814,477.85, up from ¥338,075,558.29[24] - Cash outflow from investment activities was ¥411,141,768.90, compared to ¥368,594,226.99 previously[24] - Net cash flow from investment activities was ¥96,672,708.95, a significant improvement from -¥30,518,668.70[25] - Cash inflow from financing activities totaled ¥5,001,612.87, with cash outflow at ¥19,455,891.66, leading to a net cash flow of -¥14,454,278.79[25] - The ending cash and cash equivalents balance was ¥498,223,109.74, up from ¥295,930,464.03[25] - The company received ¥506,000,000.00 from investment recoveries, a notable increase from ¥335,595,534.61[24] - The company paid ¥20,038,347.48 in taxes, compared to ¥15,562,931.31 in the previous period[24] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,433,613,832.10, an increase of 1.05% from CNY 3,397,869,333.80 at the end of the previous year[5] - As of March 31, 2025, the company's total assets amounted to RMB 3,433,613,832.10, an increase from RMB 3,397,869,333.80 as of December 31, 2024[14] - The total liabilities as of the reporting date were ¥370,989,661.66, slightly down from ¥372,532,626.44 in the previous period[18] - Total equity attributable to shareholders increased to ¥3,062,624,170.44 from ¥3,025,336,707.36, reflecting a growth of 1.2%[17] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 9,271, with no preferred shareholders[10] - The company reported a total of 21,166,362 shares held by Hainan Zhuoshihengli Investment Partnership, accounting for 12.30% of the total shares[12] - The company has a significant shareholder, Liu Xiaochun, holding 11,698,016 shares, which is 6.80% of the total shares[12] - The company has not reported any changes in the participation of major shareholders in margin trading or securities lending activities[12] Research and Development - Research and development expenses totaled CNY 31,997,620.74, which is 9.30% of operating revenue, slightly down from 9.34% in the previous year[5] - Research and development expenses for Q1 2025 amounted to ¥28,813,706.89, up from ¥26,231,980.90 in Q1 2024, showing an increase of 9.8%[20] Other Information - The company recognized non-recurring gains of CNY 3,626,058.80 during the reporting period, primarily from government subsidies and other non-operating income[7] - The weighted average return on equity increased by 0.33 percentage points to 1.50% from 1.17% year-on-year[5] - There are no significant new strategies or product developments mentioned in the conference call[13] - Total operating costs for Q1 2025 were ¥283,224,907.96, up from ¥279,789,462.12 in Q1 2024, reflecting a rise of 1.6%[20] - Cash received from sales of goods and services in Q1 2025 was ¥234,123,443.98, an increase from ¥194,895,309.25 in Q1 2024[23] - Deferred income tax liabilities were reported at ¥5,591,807.60, a slight decrease from ¥5,684,742.36[18] - The fixed assets decreased to RMB 1,060,487,612.54 from RMB 1,098,966,025.95, reflecting a decline of approximately 3.5%[15]

Financial Performance - The company's operating revenue for 2024 reached ¥1,458,698,343.66, representing a year-on-year increase of 20.74% compared to ¥1,208,162,739.17 in 2023[24]. - Net profit attributable to shareholders for 2024 was ¥251,722,494.92, an increase of 87.60% from ¥134,181,283.39 in 2023[24]. - The net profit after deducting non-recurring gains and losses was ¥237,366,716.59, reflecting a growth of 103.43% compared to ¥116,683,527.35 in 2023[24]. - Basic earnings per share for 2024 were ¥1.45, up 47.96% from ¥0.98 in 2023[25]. - The company's total assets as of the end of 2024 were ¥3,397,869,333.80, a 2.23% increase from ¥3,323,862,100.18 at the end of 2023[24]. - The weighted average return on equity increased to 8.52% in 2024, up from 4.54% in 2023, marking an increase of 3.98 percentage points[25]. - The overall gross margin for 2024 was 44.20%, an increase of 9.02 percentage points compared to 2023, driven by product structure optimization and effective cost control measures[39]. - The company achieved a revenue of 1,458.70 million RMB, representing a year-on-year growth of 20.74%[37]. - Net profit attributable to shareholders reached 251.72 million RMB, up 87.60% year-on-year, with a non-recurring net profit of 237.37 million RMB, increasing by 103.43%[37]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of 5.90 CNY per 10 shares, totaling approximately 101.54 million CNY (including tax) based on a total share capital of 172,107,058 shares[8]. - The company has not proposed any capital reserve conversion into shares or stock dividends in its profit distribution plan[8]. - The company plans to propose a mid-term dividend plan for 2024 at the upcoming shareholder meeting[180]. - The company has proposed a three-year shareholder dividend return plan for 2024-2026[198]. Governance and Internal Controls - The board of directors and management have expressed concerns regarding governance and internal controls, with specific allegations of misconduct by some management personnel[4]. - The company has received a verbal warning from the Shanghai Stock Exchange regarding issues in corporate governance, internal control execution, and financial compliance[195]. - The company has implemented effective rectifications in response to the issues raised by the Shaanxi Securities Regulatory Bureau[195]. - The company has revised its information disclosure management measures to ensure timely, accurate, and complete information disclosure, enhancing transparency and protecting investors' rights[177]. - The company actively engages with investors through multiple channels, including performance briefings and direct communication, to gather feedback and improve operational strategies[178]. Research and Development - Research and development expenses accounted for 8.30% of operating revenue in 2024, a decrease of 1.06 percentage points from 9.36% in 2023[25]. - In 2024, the company increased R&D investment to 121 million yuan, accounting for 8% of main business revenue, a 7% increase from the previous year[46]. - The company applied for 26 new patents during the reporting period, including 17 invention patents, and obtained 11 patents, bringing the total to 80[71]. - The company is focusing on expanding its pharmaceutical CDMO business into amino acids and peptides, aiming to increase domestic market penetration[63]. - The company is committed to enhancing its capabilities in biopharmaceuticals, particularly in amino acids and peptides[165]. Operational Efficiency and Risks - The company has outlined various operational risks in its management discussion and analysis section, emphasizing the need for investor awareness[5]. - The company faces risks related to customer concentration, with a high dependency on its top five clients, which could lead to performance volatility if their purchasing behavior changes[89]. - The company is exposed to potential declines in gross margins for display materials and pharmaceutical intermediates due to rising raw material costs and market demand fluctuations[92]. - The company is at risk of inventory impairment due to potential overproduction and market demand changes, which could significantly impact its financial performance[95]. - The company is focusing on optimizing production processes to achieve high yield and low energy consumption, aiming to reduce costs and improve gross margins[86]. Strategic Plans and Market Position - The company aims to reverse the declining trend and return to growth in 2024, focusing on operational efficiency and market competitiveness[36]. - The company is actively pursuing a "cooperative R&D + customized production" model to enhance competitiveness in the CDMO sector[59]. - The company aims to strengthen its position in the OLED materials sector while expanding its domestic market presence[163]. - The company is considering strategic acquisitions to enhance its market position, targeting firms with a combined revenue of $200 million[185]. - The company has set a performance guidance of $1 billion in revenue for the upcoming quarter[185]. Shareholder Engagement and Management Changes - The company held 5 shareholder meetings during the reporting period, ensuring compliance with legal requirements and providing a convenient voting method for shareholders, particularly protecting the rights of minority shareholders[173]. - The company has appointed new board members and executives, enhancing its leadership team[185]. - Liu Xiaochun, the chairman, increased his shareholding from 8,973,243 to 11,698,016 shares, a change of 2,724,773 shares due to the 2023 equity distribution[182]. - The company plans to implement a restricted stock incentive plan for 2024, with relevant proposals to be discussed at the shareholder meeting[180]. Market Trends and Industry Outlook - The global semiconductor market is projected to reach $620.2 billion in 2024, representing a year-on-year growth of approximately 17%[60]. - The global CDMO market is projected to grow from nearly $150 billion in 2023 to over $250 billion by 2030, with significant growth in the biopharmaceutical sector[160]. - The OLED technology is penetrating mid-size fields, with Chinese manufacturers expected to increase their market share due to cost and capacity advantages[158]. - The LCD market is seeing a consolidation of domestic manufacturers, enhancing their competitive edge and market share[159].

证券代码：688550 证券简称：瑞联新材 公告编号：2025-028 西安瑞联新材料股份有限公司 关于董事辞职的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 西安瑞联新材料股份有限公司（下称"公司"）董事会近日收到公司非独立 董事卢冠良先生递交的辞职报告，卢冠良先生因近期身体状况持续不佳，经慎重 考虑决定辞去公司第三届董事会董事职务。辞职后，卢冠良先生将不再担任公司 任何职务。根据《中华人民共和国公司法》等相关法律法规及《公司章程》的有 关规定，卢冠良先生的辞职不会导致公司董事会成员低于法定最低人数，不会影 响公司董事会正常运作和公司的日常生产经营，其辞职报告自送达董事会时生效。 截至本公告披露日，卢冠良先生未持有公司股票，亦不存在应当履行而未履 行的承诺事项。 公司及董事会向卢冠良先生在任职期间对公司作出的贡献表示衷心感谢！ 特此公告。 西安瑞联新材料股份有限公司董事会 2025 年 4 月 19 日 ...

西安瑞联新材料股份有限公司 2024 年度募集资金存放与使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《上市公司监管指引第2号——上市公司募集资金管理和使用的监管要求 （2022年修订）》和《上海证券交易所科创板上市公司自律监管指引第1号——规范 运作》有关规定，现将西安瑞联新材料股份有限公司（以下简称"本公司"或"公 司"）2024年度募集资金存放与使用情况说明如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到位时间 经中国证券监督管理委员会《关于同意西安瑞联新材料股份有限公司首次公开 发行股票注册的批复》（证监许可[2020]1582号），公司委托海通证券股份有限公司 承销，通过上海证券交易所系统于2020年8月20日向社会公众公开发行了普通股（A 股）股票1,755万股，股票面值为人民币1.00元，发行价为每股人民币113.72元。截至 2020年8月26日，本公司共募集资金199,578.60万元，扣除发行费用15,175.01万元后， 募集资金净额为184,403.59万元。 ...

证券代码：688550 证券简称：瑞联新材 公告编号：2025-039 西安瑞联新材料股份有限公司 关于 2025 年度董事、高级管理人员薪酬方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 西安瑞联新材料股份有限公司（下称"公司"）根据《上海证券交易所科创 板股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规 范运作》等相关法律法规以及《公司章程》《薪酬与考核委员会工作细则》的有 关规定，结合公司所处行业、地区薪酬水平等实际情况，制定了 2025 年度董事、 高级管理人员薪酬方案。现将具体情况公告如下： 一、适用对象 公司2025年度任期内的董事、高级管理人员 二、适用期限 2025年1月1日至2025年12月31日 三、薪酬方案的具体内容 1、董事薪酬方案 （1）独立董事以固定津贴形式在公司领取报酬，津贴标准为12万元/年 （税前），因履职需要产生的费用由公司承担。 （2）在公司任职的董事按其在公司担任的经营管理职务结合绩效考核结果 领取薪酬，不再领取董事津贴。 （3）其他未在公司任职的 ...

关于西安瑞联新材料股份有限公司 2024 年度募集资金存放与实际使用情况 鉴证报告 致同会计师事务所（特殊普通合伙） 目 录 关于西安瑞联新材料股份有限公司 2024 年度募集资金 存放与实际使用情况鉴证报告 西安瑞联新材料股份有限公司 2024 年度募集资金 存放与使用情况的专项报告 1-12 致同专字（2025）第 110A008660 号 西安瑞联新材料股份有限公司全体股东： 我们接受委托，对后附的西安瑞联新材料股份有限公司（以下简称"瑞 联新材公司"）《2024 年度募集资金存放与使用情况的专项报告》（以下简 称 "专项报告"）执行了合理保证的鉴证业务。 按照《上市公司监管指引第 2号——上市公司募集资金管理和使用的监管 要求（2022 年修订）》和《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》的要求编制 2024 年度专项报告，保证其内容真实、准确、 完整，不存在虚假记录、误导性陈述或重大遗漏瑞联新材公司董事会的责任， 我们的责任是在实施鉴证工作的基础上对瑞联新材公司董事会编制的 2024 年 度专项报告提出鉴证结论。 致同会计师事务所（特殊普通合伙） 中国北京 朝阳区建国门外大 ...